UBS Group’s ADC Therapeutics ADCT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.22M | Buy |
827,575
+60,511
| +8% | +$162K | ﹤0.01% | 3745 |
|
|
2025
Q1 | $1.08M | Sell |
767,064
-117,454
| -13% | -$166K | ﹤0.01% | 4140 |
|
|
2024
Q4 | $1.76M | Buy |
884,518
+844,743
| +2,124% | +$1.68M | ﹤0.01% | 3817 |
|
|
2024
Q3 | $125K | Buy |
39,775
+18,582
| +88% | +$58.5K | ﹤0.01% | 5016 |
|
|
2024
Q2 | $67K | Buy |
21,193
+21,142
| +41,455% | +$66.8K | ﹤0.01% | 5316 |
|
|
2024
Q1 | $229 | Buy |
+51
| New | +$229 | ﹤0.01% | 7534 |
|
|
2023
Q2 | – | Sell |
-11,302
| Closed | -$22K | – | 7739 |
|
|
2023
Q1 | $22K | Buy |
11,302
+8,386
| +288% | +$16.4K | ﹤0.01% | 5919 |
|
|
2022
Q4 | $11.2K | Buy |
+2,916
| New | +$11.2K | ﹤0.01% | 7237 |
|
|
2022
Q1 | – | Sell |
-2,426
| Closed | -$49K | – | 9103 |
|
|
2021
Q4 | $49K | Buy |
+2,426
| New | +$49K | ﹤0.01% | 5809 |
|
|
2021
Q3 | – | Sell |
-157
| Closed | -$4K | – | 8300 |
|
|
2021
Q2 | $4K | Hold |
157
| – | – | ﹤0.01% | 7539 |
|
|
2021
Q1 | $4K | Sell |
157
-1,308
| -89% | -$33.3K | ﹤0.01% | 7364 |
|
|
2020
Q4 | $47K | Buy |
1,465
+1,324
| +939% | +$42.5K | ﹤0.01% | 5241 |
|
|
2020
Q3 | $5K | Buy |
+141
| New | +$5K | ﹤0.01% | 6401 |
|